“But as I said, just to start with, it will not be enough because first of all, we should remember that innovative therapies will have to be reserved for critically ill patients and will be used prudently. So that means that if you have new antimicrobials, new antibiotics, new therapies, but you don't take all the measures that need to go with it after a very quickly a few few years, your innovation will be out. It will not work anymore. So. And there I come back to what was already said by certain speakers that prudent use and stewardship, infection and control and prevention measures, uh, surveillance is key. We have also heard about the importance to work in the one health approach, to see all the links between the human, the animal and the environment. Awareness is key. Here we speak about Amr going to the in the street and ask people Amr. They will not understand most of the people we we had, we have done two years ago a Eurobarometer and half of the people did not know that antibiotics are not effective against viruses. We will do another one next year. Hopefully we will have other results, but I'm not sure about that. So awareness education, training is key. And of course engage with all the actors. Now, I would I would like also to say, we hear that Amr has no borders. We need a collective approach. We need to work with all sectors. But we need to remember that member states are in different situations.”
Public and private sectors role in healthcare services · Antimicrobial resistance
“Many thanks and dear members and dear guests, you can imagine that as the head of the unit dealing with Amr and one health, the topic is very interesting and important to us and we appreciate it a lot. The questions and answers and all the presentations that have been given. So Amr is a serious issue. And um, I think there is no point to discuss about the need for intervention. Uh, it's necessary. It's crucial. But I would like to say from the start it will not be enough. Uff. Um, let's not go back to the push and pull incentives. You may know that this morning the last technical trialogue took place that there will be a political trialogue, the 10th of this week. So where I hope under the Danish presidency, there will be a possibility to to have finally an agreement and to see if all the provisions that are at stake will be finally decided on and with good outcome. Um, so we have different ways to, uh, I would say incentivize the, the innovation being regulatory. As I said, the pharma package is there and also financial. I would say more about push incentives. It's clear money is needed. Uh, from the Commission. 1 billion was invested over the last ten years and mobilized for research and innovation. Uh, now 75 million millions will be put in the new One health Amr partnership, so hopefully this will help the issue. We have heard a lot about toolbox of incentives and that all incentives are complementary. We had a very nice presentation regarding phage therapy indeed, and I hope also that there we will find a way to have a quicker way to assess and put, I would say, the authorization on these therapies within the pharma package.”
Antimicrobial resistance
“They are in different epidemiological contexts. They have different diseases, different climatic conditions. They have different healthcare practices. They have different social behaviours. Um, the level of awareness is absolutely not the same in all member states. And we spoke about that. The access to antibiotics is not the same either. Member. The smallest member states have more difficulties to have access to the right antibiotic. Not to say about the need to have a quick diagnostic tools, all that are measures that if we don't take them as seriously as to go for innovation, we will remain with this very difficult situation, addressing antimicrobial. So I would just like to conclude by saying that we need absolutely. I would say a one health approach with, I would say all the sectors concerned. We need also as EU to be positioned, as I would say, the leader, in finding concrete solutions, taking into consideration that we have a lot of SMEs. Finally, and it's also part of what I was trying to say. No single member state, no single action will be able to address the issue. And that's why it's so complex, because we need to act all where we can the best and make it sure that it happens. And it's quite urgent now to act because certain members highlighted the figures. I can only confirm them from Ecdc. They do not look good. Hopefully it was the result of 2024. Since then we have taken a lot of actions. I hope that next year we see the first positive results of this. Thank you very much.”
Public and private sectors role in healthcare services · Antimicrobial resistance